Search and analyze individual stocks with comprehensive metrics
Valiant Laboratories Ltd
Fundamental Score
Valiant Laboratories Ltd Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of VALIANTLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (104.22%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Strong Revenue Growth (115.08%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Conservative Debt Levels (D/E: 0.17)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (17.53x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Balanced Promoter Holding (74.94%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
9 factors identified
Below-Average Return on Equity (-1.43%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.95%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Premium Valuation Risk (P/E: 72.54x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Valiant Laboratories Ltd
About VALIANTLAB
Company Details
Market Information
Performance
VALIANTLAB Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of VALIANTLAB?
VALIANTLAB is currently trading at ₹74.98 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of VALIANTLAB shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of VALIANTLAB and what does it mean?
VALIANTLAB has a P/E ratio of 72.54x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹73 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is VALIANTLAB performing according to Bull Run's analysis?
VALIANTLAB has a Bull Run fundamental score of 31.9/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: -1.43%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does VALIANTLAB belong to?
VALIANTLAB operates in the Pharmaceuticals industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Valiant Laboratories Ltd. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for VALIANTLAB?
VALIANTLAB has an ROE of -1.43%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Valiant Laboratories Ltd generates profits from shareholders' equity. An ROE of -1% means the company generates ₹-1 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is VALIANTLAB's debt-to-equity ratio and what does it indicate?
VALIANTLAB has a debt-to-equity ratio of 0.17, which indicates conservative financing with low financial risk. This means the company has ₹17 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is VALIANTLAB's dividend yield and is it a good dividend stock?
VALIANTLAB offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has VALIANTLAB grown over the past 5 years?
VALIANTLAB has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in VALIANTLAB and why does it matter?
Promoters hold 74.94% of VALIANTLAB shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.
How does VALIANTLAB compare with its industry peers?
VALIANTLAB trades at P/E 72.54x vs industry average 31.77x, with ROE of -1.43% and ROCE of -0.95%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether VALIANTLAB is outperforming its competitive set in profitability, growth, and valuation metrics.
What is VALIANTLAB's market capitalization and what category does it fall into?
VALIANTLAB has a market capitalization of ₹368 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for VALIANTLAB?
Key ratios for VALIANTLAB: ROE -1.43% (Needs improvement), ROCE -0.95%, P/E 72.54x, Debt-to-Equity 0.17, Interest Coverage 17.53x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is VALIANTLAB stock and what is its beta?
VALIANTLAB has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for VALIANTLAB?
VALIANTLAB has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹74.98, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in VALIANTLAB?
Key risks for VALIANTLAB include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.17), and operational challenges. The stock has a Fundamental Score of 31.9/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is VALIANTLAB's operating profit margin and how has it trended?
VALIANTLAB has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is VALIANTLAB's quarterly performance in terms of sales and profit growth?
VALIANTLAB's recent quarterly performance shows YoY Sales Growth of 115.08% and YoY Profit Growth of 104.22%. This strong double-digit growth indicates excellent business momentum and management execution. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in VALIANTLAB?
VALIANTLAB has FII holding of 0.02% and DII holding of 0.00%, totaling 0.02% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.